Intestinal microbiome: a new target for chalaziosis treatment in children?
Chalaziosis
Children
Microbiome
Probiotics
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
26
05
2020
accepted:
18
11
2020
revised:
06
11
2020
pubmed:
24
11
2020
medline:
24
6
2021
entrez:
23
11
2020
Statut:
ppublish
Résumé
Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence. A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy). All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 ("retrospectively registered").Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way. What is Known: • The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target. • Probiotics play a role in the prevention and treatment of different conditions in children. What is New: • In children probiotic supplementation is safe and effective. • Probiotic supplementation reduced the time required for complete resolution of the chalazion.
Identifiants
pubmed: 33226501
doi: 10.1007/s00431-020-03880-5
pii: 10.1007/s00431-020-03880-5
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1293-1298Références
George Kerry R, Patra JK, Gouda S, Park Y, Shin HS, Das G (2018) Benefaction of probiotics for human health: a review. J Food Drug Anal 26(3):927–939. https://doi.org/10.1016/j.jfda.2018.01.002
doi: 10.1016/j.jfda.2018.01.002
pubmed: 29976412
Food and Agriculture Organization and World Health Organization Expert Consultation (2001) Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Córdoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization. Available from:. http://www.fao.org/3/a-a0512e.pdf Accessed: 29 March 2020
McLean MH, Dieguez D Jr, Miller LM, Young HA (2015) Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 64(2):332–341. https://doi.org/10.1136/gutjnl-2014-308514
doi: 10.1136/gutjnl-2014-308514
pubmed: 25416067
Scher JU, Littman DR, Abramson SB (2016) Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheum 68(1):35–45. https://doi.org/10.1002/art.39259
doi: 10.1002/art.39259
Ochoa-Reparaz J, Kasper LH (2017) The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. Transl Res 179:126–138. https://doi.org/10.1016/j.trsl.2016.07.016
doi: 10.1016/j.trsl.2016.07.016
pubmed: 27519147
Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, Ali MH, Sharma S, Tyagi M, Shivaji S (2018) Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye. Indian J Microbiol 58(4):457–469. https://doi.org/10.1007/s12088-018-0746-9
doi: 10.1007/s12088-018-0746-9
pubmed: 30262956
pmcid: 6141402
Iovieno A, Lambiase A, Sacchetti M, Stampachiacchiere B, Micera A, Bonini S (2008) Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 246(3):435–441. https://doi.org/10.1007/s00417-007-0682-6
doi: 10.1007/s00417-007-0682-6
pubmed: 18040708
Tavakoli A, Flanagan JL (2019) The case for a more holistic approach to dry eye disease: is it time to move beyond antibiotics? Antibiotics (Basel) 8(3):E88. https://doi.org/10.3390/antibiotics8030088
doi: 10.3390/antibiotics8030088
Lin P (2018) The role of intestinal microbiome in ocular inflammatory disease. Curr Opin Ophthalmol 29(3):261–266. https://doi.org/10.1097/ICU.0000000000000465
doi: 10.1097/ICU.0000000000000465
pubmed: 29538183
Baim AD, Movahedan A, Farooq AV, Skondra D (2019) The microbiome and ophthalmic disease. Exp Biol Med (Maywood) 244(6):419–429. https://doi.org/10.1177/1535370218813616
doi: 10.1177/1535370218813616
Cavuoto KM, Banerjee S, Galor A (2019) Relationship between the microbiome and ocular health. Ocul Surf 17(3):384–392. https://doi.org/10.1016/j.jtos.2019.05.006
doi: 10.1016/j.jtos.2019.05.006
pubmed: 31125783
Lin P (2019) Importance of the intestinal microbiota in ocular inflammatory diseases: a review. Clin Exp Ophthalmol 47(3):418–422. https://doi.org/10.1111/ceo.13493
doi: 10.1111/ceo.13493
pubmed: 30834680
Sansotta N, Peroni DG, Romano S, Rugiano A, Vuilleumier P, Baviera G, Italian Society of Pediatric Allergy, Immunology (SIAIP), Microbiota Committee, Italy (2019) The good bugs: the use of probiotics in pediatrics. Curr Opin Pediatr 31(5):661–669. https://doi.org/10.1097/MOP.0000000000000808
doi: 10.1097/MOP.0000000000000808
pubmed: 31356353
Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY (2019) Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol 19(1):110. https://doi.org/10.1186/s12886-019-1118-x
doi: 10.1186/s12886-019-1118-x
pubmed: 31088416
pmcid: 6518763
Nemet AY, Vinker S, Kaiserman I (2011) Associated morbidity of chalazia. Cornea. 30(12):1376–1381. https://doi.org/10.1097/ICO.0b013e31821de36f
doi: 10.1097/ICO.0b013e31821de36f
pubmed: 21993469
Yam JC, Tang BS, Chan TM, Cheng AC (2014) Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol 24(2):159–163. https://doi.org/10.5301/ejo.5000341
doi: 10.5301/ejo.5000341
pubmed: 23873491
Bonifazi E (2005) Linear chalaziosis. Eur J Pediatr Dermatol 15(3):183
Burkhart CG, Burkhart CN (2008) Similar to acne vulgaris, bacteria may produce the biological glue that causes plugging of the meibomian gland leading to chalazions. Clin Exp Ophthalmol 36(3):295. https://doi.org/10.1111/j.1442-9071.2008.01714.x
doi: 10.1111/j.1442-9071.2008.01714.x
pubmed: 18412605
Malekahmadi M, Farrahi F, Tajdini A (2017) Serum vitamin a levels in patients with chalazion. Med Hypothesis Discov Innov Ophthalmol 6(3):63–66
pubmed: 29392144
pmcid: 5787024
Lu LJ, Liu J (2016) Human microbiota and ophthalmic disease. Yale J Biol Med 89(3):325–330
pubmed: 27698616
pmcid: 5045141
Giacomin AL (2016) Infective and inflammatory eyelid disorders: conventional and unconventional therapies to maintain eye health and avoid lid surgery. EC Ophthalmology 3(6):435–445
Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P (2013) Placebo effects in children: a review. Pediatr Res 74(1):96–102. https://doi.org/10.1038/pr.2013.66
doi: 10.1038/pr.2013.66
pubmed: 23598811
Petersen C, Round JL (2014) Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16:1024–1033. https://doi.org/10.1111/cmi.12308
doi: 10.1111/cmi.12308
pubmed: 24798552
pmcid: 4143175
Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G (2018) A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 6(1):221. https://doi.org/10.1186/s40168-018-0603-4
doi: 10.1186/s40168-018-0603-4
pubmed: 30545401
pmcid: 6292067
Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S (2009) In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol 19(5):708–716. https://doi.org/10.1177/112067210901900504
doi: 10.1177/112067210901900504
pubmed: 19787586
Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 52(4):2050–2064. https://doi.org/10.1167/iovs.10-6997g
doi: 10.1167/iovs.10-6997g
pubmed: 21450919
pmcid: 3072163
Trujillo-Vargas CM, Schaefer L, Alam J, Pflugfelder SC, Britton RA, de Paiva CS (2019) The gut –eye-lacrimal gland-micobiome axis in Sjogren syndrome. Ocul Surf S1542-0124(19):30348–30349. https://doi.org/10.1016/j.jtos.2019.10.006
doi: 10.1016/j.jtos.2019.10.006
Kugadas A, Wright Q, Geddes-McAlister J, Gadjeva M (2017) Role of microbiota in strengthening ocular mucosal barrier function through secretory IgA. Invest Ophthalmol Vis Sci 58(11):4593–4600. https://doi.org/10.1167/iovs.17-22119
doi: 10.1167/iovs.17-22119
pubmed: 28892827
pmcid: 5595225
Rizk M, Tuzmen S (2020) MicroRNAs and microbiota: is there a cross talk? Drugs Today 56(3):211–226. https://doi.org/10.1358/dot.2020.56.3.3079409
doi: 10.1358/dot.2020.56.3.3079409
Nayyar A, Gindina S, Barron A, Hu Y, Danias J (2020) Do epigenetic changes caused by commensal microbiota contribute to development of ocular disease? A review of evidence. Hum Genomics 14:11. https://doi.org/10.1186/s40246-020-00257-5
doi: 10.1186/s40246-020-00257-5
pubmed: 32169120
pmcid: 7071564
Verhagen FH, Bekker CPJ, Rossato M, Hiddingh S, de Vries L, Devaprasad A, Pandit A, Ossewaarde-van Norel J, ten Dam N, Moret-Pot MCA, Imhof SM, de Boer JH, Radstake TRDJ, Kuiper JJW (2018) A disease-associated microRNA cluster links inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis. Invest Ophthalmol Vis Sci 59(2):878–888. https://doi.org/10.1167/iovs.17-23643
doi: 10.1167/iovs.17-23643
pubmed: 29435587
Alvarez-Olmos MI, Oberhelman RA (2001) Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 32:1567–1576. https://doi.org/10.1086/320518
doi: 10.1086/320518
pubmed: 11340528
Rusu E, Enache G, Cursaru R et al (2019) Prebiotics and probiotics in atopic dermatitis. Exp Ther Med 18(2):926–931. https://doi.org/10.3892/etm.2019.7678
doi: 10.3892/etm.2019.7678
pubmed: 31384325
pmcid: 6639913
Thomas DW, Greer FR, Committee on Nutrition; Section on Gastroenterology, Hepatology, and Nutrition (2010) Clinical report—probiotics and prebiotics in pediatrics. Pediatrics 126:1217–1231. https://doi.org/10.1542/peds.2010-2548
doi: 10.1542/peds.2010-2548
pubmed: 21115585
Dong Q, Brulc JM, Iovieno A, Bates B, Garoutte A, Miller D, Revanna KV, Gao X, Antonopoulos DA, Slepak VZ, Shestopalov VI (2011) Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci 52(8):5408–5413. https://doi.org/10.1167/iovs.10-6939
doi: 10.1167/iovs.10-6939
pubmed: 21571682
pmcid: 3176057
Cavuoto KM, Mendez R, Miller D, Galor A, Banerjee S (2018) Effect of clinical parameters on the ocular surface microbiome in children and adults. Clin Ophthalmol 12:1189–1197. https://doi.org/10.2147/OPTH.S166547
doi: 10.2147/OPTH.S166547
pubmed: 30013312
pmcid: 6040630
Cavuoto KM, Banerjee S, Miller D, Galor A (2018) Composition and comparison of the ocular surface microbiome in infants and older children. Transl Vis Sci Technol 7(6):16. https://doi.org/10.1167/tvst.7.6.16
doi: 10.1167/tvst.7.6.16
pubmed: 30519501
pmcid: 6269136
Ozkan J, Nielsen S, Diez-Vives C, Coroneo M, Thomas T, Willcox M (2017) Temporal stability and composition of the ocular surface microbiome. Sci Rep 7(1):9880. https://doi.org/10.1038/s41598-017-10494-9
doi: 10.1038/s41598-017-10494-9
pubmed: 28852195
pmcid: 5575025
Kugadas A, Gadjeva M (2016) Impact of microbiome on ocular health. Ocul Surf 3:342–349. https://doi.org/10.1016/j.jtos.2016.04.004
doi: 10.1016/j.jtos.2016.04.004